Dynavax Technologies Co. (NASDAQ:DVAX) Director Francis Cano sold 2,000 shares of the stock in a transaction that occurred on Thursday, December 6th. The stock was sold at an average price of $10.47, for a total value of $20,940.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of Dynavax Technologies stock traded down $0.16 on Friday, reaching $10.54. 841,769 shares of the company’s stock were exchanged, compared to its average volume of 703,972. The stock has a market capitalization of $670.80 million, a price-to-earnings ratio of -6.09 and a beta of 0.46. Dynavax Technologies Co. has a 52 week low of $9.63 and a 52 week high of $22.80. The company has a debt-to-equity ratio of 1.03, a quick ratio of 5.90 and a current ratio of 6.29.
Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). The business had revenue of $1.46 million for the quarter, compared to the consensus estimate of $3.16 million. Dynavax Technologies had a negative return on equity of 97.79% and a negative net margin of 5,044.85%. Dynavax Technologies’s quarterly revenue was up 2822.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.38) earnings per share. On average, equities research analysts forecast that Dynavax Technologies Co. will post -2.51 EPS for the current year.
Several large investors have recently modified their holdings of the company. JPMorgan Chase & Co. raised its position in shares of Dynavax Technologies by 1.8% during the third quarter. JPMorgan Chase & Co. now owns 264,669 shares of the biopharmaceutical company’s stock worth $3,282,000 after purchasing an additional 4,591 shares during the period. Wells Fargo & Company MN raised its position in shares of Dynavax Technologies by 6.0% during the third quarter. Wells Fargo & Company MN now owns 87,721 shares of the biopharmaceutical company’s stock worth $1,087,000 after purchasing an additional 4,979 shares during the period. Patriot Financial Group Insurance Agency LLC raised its position in shares of Dynavax Technologies by 39.2% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 29,170 shares of the biopharmaceutical company’s stock worth $362,000 after purchasing an additional 8,220 shares during the period. Alps Advisors Inc. raised its position in shares of Dynavax Technologies by 11.2% during the second quarter. Alps Advisors Inc. now owns 90,375 shares of the biopharmaceutical company’s stock worth $1,378,000 after purchasing an additional 9,103 shares during the period. Finally, Quantbot Technologies LP acquired a new position in shares of Dynavax Technologies during the third quarter worth approximately $131,000. 76.73% of the stock is currently owned by institutional investors.
DVAX has been the topic of a number of research analyst reports. Cantor Fitzgerald restated a “buy” rating and set a $30.00 price target on shares of Dynavax Technologies in a report on Monday, October 1st. ValuEngine upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Tuesday, October 23rd. BidaskClub cut Dynavax Technologies from a “sell” rating to a “strong sell” rating in a report on Saturday, August 18th. Cowen restated a “buy” rating and set a $30.00 price target on shares of Dynavax Technologies in a report on Monday, October 22nd. Finally, Royal Bank of Canada cut their price target on Dynavax Technologies from $26.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, November 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Dynavax Technologies currently has an average rating of “Hold” and a consensus target price of $28.00.
TRADEMARK VIOLATION WARNING: “Dynavax Technologies Co. (DVAX) Director Sells $20,940.00 in Stock” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/12/08/dynavax-technologies-co-dvax-director-sells-20940-00-in-stock.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Featured Story: How does inflation affect different investments?
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.